Trisomy 13 (T13)

Laboratory assay overview

QNatal® Advanced is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome) and certain sex chromosome abnormalities (i.e., 45,X, 47,XXY, 47,XXX, and 47,XYY). In addition, if selected as an option, QNatal Advanced can screen for certain microdeletions (i.e., 22q, 5p, 1p36, 15q, 11q, 8q, and 4p) that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Advanced is not recommended before 10 weeks of gestation due to a significantly increased risk of a failed result. QNatal Advanced is a screening test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of this screening test alone. As with any test, there may be false positives or false negatives. All results should be interpreted in the context of pertinent clinical findings, relevant obstetric history and laboratory data based on a clear understanding of the value and limitations of the test data. The positive predictive value varies by patient risk factors as well as by genetic marker, and may be lower for rare conditions. Performance data for QNatal® Advanced may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

Laboratory assay overview

QNatal Chr 13,18,21, SCA is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome), certain sex chromosome abnormalities (i.e., 45,X, 47,XXY, 47,XXX, and 47,XYY), and/or fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Chr 13,18,21, SCA is not recommended before 10 weeks gestation due to a significantly increased risk of a failed result. QNatal Chr 13,18,21, SCA is a screening test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of this screening test alone. As with any test, there may be false positives or false negatives. All results should be interpreted in the context of pertinent clinical findings, relevant obstetric history and laboratory data based on a clear understanding of the value and limitations of the test data. The positive predictive value varies by patient risk factors as well as by genetic marker and may be lower for rare conditions. Performance data for the QNatal Chr 13,18,21, SCA may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

Laboratory assay overview

QNatal Chr 13,18,21, SCA, 22q Microdel is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome) and certain sex chromosome abnormalities (i.e., 45,X, 47,XXY, 47,XXX, and 47,XYY). In addition, QNatal Chr 13,18,21, SCA, 22q Microdel screens for 22q microdeletions that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Chr 13,18,21, SCA, 22q Microdel is not recommended before 10 weeks of gestation due to a significantly increased risk of a failed result. QNatal Chr 13,18,21, SCA, 22q Microdel is a screening test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of this screening test alone. As with any test, there may be false positives or false negatives. All results should be interpreted in the context of pertinent clinical findings, relevant obstetric history and laboratory data based on a clear understanding of the value and limitations of the test data. The positive predictive value varies by patient risk factors as well as by genetic marker, and may be lower for rare conditions. Performance data for QNatal Chr 13,18,21, SCA, 22q Microdel may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

Laboratory assay overview

QNatal Chr 13,18,21, SCA, Microdels is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18 (Edwards Syndrome), Trisomy 13 (Patau Syndrome) and certain sex chromosome abnormalities (i.e., 45,X, 47,XXY, 47,XXX, and 47,XYY). In addition, QNatal Chr 13,18,21, SCA, Microdels screens for certain microdeletions (i.e., 22q, 5p, 1p36, 15q, 11q, 8q, and 4p) that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Chr 13,18,21, SCA, Microdels is not recommended before 10 weeks of gestation due to a significantly increased risk of a failed result. QNatal Chr 13,18,21, SCA, Microdels is a screening test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of this screening test alone. As with any test, there may be false positives or false negatives. All results should be interpreted in the context of pertinent clinical findings, relevant obstetric history and laboratory data based on a clear understanding of the value and limitations of the test data. The positive predictive value varies by patient risk factors as well as by genetic marker, and may be lower for rare conditions. Performance data for QNatal Chr 13,18,21, SCA may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).